LYMErix Two-Dose Efficacy Data Provides 1999 Tick Season Benchmark
Executive Summary
Two-dose efficacy data included in labeling for SmithKline Beecham's LYMErix will provide an efficacy benchmark for use of the vaccine in anticipation of the 1999 Lyme disease season.
You may also be interested in...
Lymerix Two-Month Dose Expected By Mid-2000, Pediatric Data By Year-End
SmithKline Beecham's Lymerix two-month accelerated dosing regimen could receive FDA approval in the first half of 2000, Jean-Pierre Garnier, PhD, said Sept. 16 at the Bear Stearns health care conference in New York City.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011